Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: Results from the Eastern Cooperative Oncology Group E2197 study

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 683-692

  Solin, Lawrence J ^a   Gray, Robert ^b,c   Goldstein, Lori J ^d   Recht, Abram ^e   Baehner, Frederick L ^f   Shak, Steven ^f   Badve, Sunil ^g   Perez, Edith A ^h   Shulman, Lawrence N ^b   Martino, Silvana ⁱ   Davidson, Nancy E ^j   Sledge Jr , George W ^g   Sparano, Joseph A ^k  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Eastern Cooperative Oncology Group   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f Genomic Health Inc   (United States)

^g INDIANA UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

ⁱ Angeles Clinic and Research Institute   (United States)

^j UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

21 gene recurrence score; Breast conservation treatment; Early stage breast carcinoma; Local recurrence; Local regional recurrence; Radiation treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTOME;

EID: 84868194039     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2072-y     Document Type: Article

References (29)

1. Mamounas EP, Tang G, Fisher B et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677-1683
2. Kreike B, Halfwerk H, Armstrong N et al (2009) Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 15:4181-4190
3. Nuyten DS, Kreike B, Hart AA et al (2006) Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62
4. Voduc KD, Cheang M, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691
5. Millar EK, Graham PH, O'Toole SA et al (2009) Prediction of local recurrence, distant metastasis, and death after breast-conserving therapy in early-stage invasive breast cancer using a fivebiomarker panel. J Clin Oncol 27:4701-4708
6. Solin LJ, Hwang W-T, Vapiwala N (2009) Outcome after breast conservation treatment with radiation for women with triplenegative early-stage invasive breast carcinoma. Clin Breast Cancer 9:96-100
7. Freedman GM, Anderson PR, Li T et al (2009) Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 115:946-951
8. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657
9. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434
10. Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378
11. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334
12. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235-244
13. Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25-32
14. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568-2581
15. Hernandez-Aya LF, Chavez-MacGregor M, Lei X et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29:2628-2634
16. Abdulkarim BS, Cuartero J, Hanson J et al (2011) Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 29:2852-2857
17. Goldstein LJ, O'Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E2197. J Clin Oncol 26:4092-4099
18. Goldstein LJ, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071
19. Sparano JA, Goldstein LJ, Childs BH et al (2009) Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 15:7693-7700
20. Badve SS, Baehner FL, Gray RP et al (2008) Estrogen-and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481
21. Gray RJ (2009) Weighted analysis for cohort sampling designs. Lifetime Data Anal 15:24-40
22. Ruan PK, Gray RJ (2008) Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med 27:5709-5724
23. Harris EE, Hwang W-T, Lee EA et al (2006) The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. Breast J 12:431-436
24. Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptorpositive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
25. Tang G, Shak S, Paik S et al (2011) Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvanti for women with node-negative, ER-positive breast cancer: results from NSABP-B-14 and NSABP B-20. Breast Cancer Res Treat 127:133-142
26. Cabioglu N, Hunt KK, Buchholz TA et al (2005) Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer 104:20-29
27. Pass H, Vicini FA, Kestin LL et al (2004) Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution. Cancer 101:713-720
28. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
29. Halyard MY, Dueck AC, Pisansky TM et al (2010) Impact of adjuvant trastuzumab on local regional recurrence: Data from the North Central Cancer Treatment Group (NCCTG) N9831 study (). Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, 8-12 December 2010